Merck & Co., Inc. (MRK)
| Market Cap | 202.94B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.50B |
| EPS (ttm) | 6.49 |
| PE Ratio | 12.53 |
| Forward PE | 8.87 |
| Dividend | $3.24 (3.99%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 2,317,653 |
| Open | 81.22 |
| Previous Close | 81.14 |
| Day's Range | 80.82 - 81.69 |
| 52-Week Range | 73.31 - 119.38 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 107.21 (+31.95%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $107.21, which is an increase of 31.95% from the latest price.
News
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its mul...
Oakmark Funds' Bill Nygren: Here's where to look beyond the Mag 7
Bill Nygren, Oakmark Funds partner and CIO, joins CNBC's 'Closing Bell' to discuss where to find market opportunities outside of tech, why he's keeping an eye on Corebridge Financial and Delta Airline...
Merck: Buy This Dividend Powerhouse While It's Cheap
Merck offers a compelling opportunity for long-term income and value investors, trading near its 52-week low with a 4% dividend yield. MRK's robust drug pipeline, strong balance sheet, and strategic a...
Merck's pneumonia shot shows promise in late-stage study
Drugmaker Merck said on Thursday that its pneumonia shot showed strong immune responses in children and teens who are at higher risk of serious illness, based on results from a late-stage study presen...
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease.
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging busi...
US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs
New blow to UK's key life science sector as industry body warns country is losing ground on investment and research
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Merck to scrap London drug research centre
Merck said on Wednesday it was scrapping research operations in London, citing the UK's challenging business environment.
US FDA to step up enforcement of pharma ads, sends enforcement letters
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...
Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Merck & Co., Inc. (NYSE:MRK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Robert Davis - Chairman, President & CEO Eliav Barr - Chief Med...
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Merck & Co., Inc. (NYSE:MRK) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:50 AM EDT Company Participants Eliav Barr - Chief Medical Officer & Head of Global Clinical Develo...
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING--(BUSINESS WIRE)-- #AntibodyDrugDiscovery--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of ...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for i...
Merck's cholesterol drug meets main goal in late-stage trial
Drugmaker Merck's oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June.
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3.
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Top 10 High-Yield Dividend Stocks For September 2025
My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively ...
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.
Merck: Buy the Next Dip Despite Short-Term Pressures
Merck's Q2 2025 results highlight strong growth in Keytruda and Animal Health, while its bullish chart pattern and low valuation make it a compelling long-term buy.
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 2025 Wells Fargo Healthcare Conference.